Application
Western blot analysis of SH3BGRL3 Antibody (Center) in Neuro2a cell line lysates (35ug/lane). SH3BGRL3 (arrow) was detected using the purified Pab.Application
Formalin-fixed and paraffin-embedded human brain tissue reacted with SH3BGRL3 Antibody (Center), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.| Product Name | SH3BGRL3 Antibody (Center) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | SH3BGRL3; SH3 domain-binding glutamic acid-rich-like protein 3; SH3 domain-binding protein 1 |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WBIHC |
| WB:1:100~500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | SH3BGRL3 SH3 domain-binding glutamic acid-rich-like protein 3 SH3 domain-binding protein 1 |
|---|---|
| Molecular Weight(MW) | 10438 Da |
| Function | Could act as a modulator of glutaredoxin biological activity |
| Tissue Specificity | Ubiquitous. |
| Cellular Localization | Cytoplasm. Nucleus. |
| Entrez Gene | 83442 |
|---|
Application
Western blot analysis of SH3BGRL3 Antibody (Center) in Neuro2a cell line lysates (35ug/lane). SH3BGRL3 (arrow) was detected using the purified Pab.
Application
Formalin-fixed and paraffin-embedded human brain tissue reacted with SH3BGRL3 Antibody (Center), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.| Application Notes | WB:1:100~500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
